Abstract
To appraise the methodological quality of the Italian pharmaco -
economic models.
Background: In most of the developed countries the institution of HTA
agencies has been one of the major concerns in order to support the decisions
for reimbursement of new drugs. Italy is experiencing a remarkable lack in
this field.
Design: 18 Italian models published between 1998 and 2005 selected using
EMBASE and MEDLINE search engines. Inclusion criteria: (a) Italian
nationality of the first author, (b) Italian baseline population. Studies were
appraised using the checklist developed by Philips et al. (2004).
Results: Although the alternatives and the basic framework of the
pharmacoeconomic models are usually well defined and specified, the studies
present a lack of data about treatment effects, utilities, analysis of uncertainty,
considerations about heterogeneity and generalisability of results.
Conclusion: Despite the high level of competence of the authors, the
pharmacoeconomic models quality is largely affected by the scarce interest
of Italian institutions for the use of ICER-based criteria, in favour of a priceminimization
one. The institutional use of ICER-based criteria should be
strongly recommended for a rational resource use in healthcare.
Titolo tradotto del contributo | [Autom. eng. transl.] The use of decision models for the economic evaluations of drugs in Italy: state of the art and future prospects |
---|---|
Lingua originale | Italian |
pagine (da-a) | 59-74 |
Numero di pagine | 16 |
Rivista | PHARMACOECONOMICS, ITALIAN RESEARCH ARTICLES |
Volume | 9 |
Stato di pubblicazione | Pubblicato - 2007 |
Keywords
- modelli decisionali